<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28076331</article-id><article-id pub-id-type="pmc">5354681</article-id><article-id pub-id-type="publisher-id">14551</article-id><article-id pub-id-type="doi">10.18632/oncotarget.14551</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kok</surname><given-names>Dieuwertje E.G.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kiemeney</surname><given-names>Lambertus A.L.M.</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Verhaegh</surname><given-names>Gerald W.</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schalken</surname><given-names>Jack A.</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Lin</surname><given-names>Emile N.J.T.</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Michiel Sedelaar</surname><given-names>J.P.</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Alfred Witjes</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hulsbergen - van de Kaa</surname><given-names>Christina A.</given-names></name><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>van't Veer</surname><given-names>Pieter</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kampman</surname><given-names>Ellen</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Afman</surname><given-names>Lydia A.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands</aff><aff id="A2"><sup>2</sup> Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands</aff><aff id="A3"><sup>3</sup> Department of Urology, Radboud university Medical Center, Nijmegen, The Netherlands</aff><aff id="A4"><sup>4</sup> Strahlentherapie Bonn Rhein Sieg, Wesel, Germany</aff><aff id="A5"><sup>5</sup> Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Lydia A. Afman,</italic><email>lydia.afman@wur.nl</email></corresp></author-notes><pub-date pub-type="collection"><day>7</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>6</day><month>1</month><year>2017</year></pub-date><volume>8</volume><issue>6</issue><fpage>10565</fpage><lpage>10579</lpage><history><date date-type="received"><day>6</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Kok et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>In parallel with the inconsistency in observational studies and chemoprevention trials, the mechanisms by which selenium affects prostate cancer risk have not been elucidated. We conducted a randomized, placebo-controlled trial to examine the effects of a short-term intervention with selenium on gene expression in non-malignant prostate tissue. Twenty-three men received 300 &#x003bc;g selenium per day in the form of selenized yeast (n=12) or a placebo (n=11) during 5 weeks. Prostate biopsies collected from the transition zone before and after intervention were analysed for 15 participants (n=8 selenium, n=7 placebo). Pathway analyses revealed that the intervention with selenium was associated with down-regulated expression of genes involved in cellular migration, invasion, remodeling and immune responses. Specifically, expression of well-established epithelial markers, such as E-cadherin and epithelial cell adhesion molecule <italic>EPCAM</italic>, was up-regulated, while the mesenchymal markers vimentin and fibronectin were down-regulated after intervention with selenium. This implies an inhibitory effect of selenium on the epithelial-to-mesenchymal transition (EMT). Moreover, selenium was associated with down-regulated expression of genes involved in wound healing and inflammation; processes which are both related to EMT. In conclusion, our explorative data showed that selenium affected expression of genes implicated in EMT in the transition zone of the prostate.</p></abstract><kwd-group><kwd>selenium</kwd><kwd>prostatic neoplasms</kwd><kwd>gene expression</kwd><kwd>microarray</kwd><kwd>EMT</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Based on early observational and intervention studies, it has been suggested that an adequate status or intake of selenium may protect against prostate cancer [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R4" ref-type="bibr">4</xref>]. The Nutritional Prevention of Cancer (NPC) trial showed that 200 &#x003bc;g selenized yeast per day reduced the incidence of prostate cancer, and advanced prostate cancer in particular [<xref rid="R2" ref-type="bibr">2</xref>]. More recent studies, however, did not consistently confirm a protective effect of selenium for prostate cancer [<xref rid="R5" ref-type="bibr">5</xref>&#x02013;<xref rid="R8" ref-type="bibr">8</xref>]. Results of the Selenium and Vitamin E Cancer Prevention (SELECT) trial demonstrated that supplements with 200 &#x003bc;g <italic>L</italic>-selenomethionine did not decrease the incidence of prostate cancer among men in the general population [<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R9" ref-type="bibr">9</xref>]. For men with high toenail selenium levels, a slightly increased risk of high-grade prostate cancer was found after supplementation with selenium [<xref rid="R7" ref-type="bibr">7</xref>]. Similarly, in men at high risk for prostate cancer, 200-400 &#x003bc;g of selenized yeast per day was not effective for prostate cancer prevention [<xref rid="R8" ref-type="bibr">8</xref>].</p><p>The relatively high baseline selenium levels of the participants are often considered a plausible explanation for the unanticipated findings of subsequent trials as compared to the early NPC trial [<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R11" ref-type="bibr">11</xref>]. Intake and status of selenium in most European countries are relatively low as compared to the USA [<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R12" ref-type="bibr">12</xref>]. This supports further exploration of the role of selenium for prostate cancer prevention in these populations with marginal selenium status [<xref rid="R11" ref-type="bibr">11</xref>]. Rather than initiating another large intervention trial, we advocate to first gain further insight into the mechanisms underlying the role of selenium in cancer biology and other health related outcomes.</p><p>In parallel with the inconsistency in observational studies and chemoprevention trials, the mechanisms by which selenium may affect prostate cancer risk have not been elucidated. Supplementation with selenium resulted in increased levels of selenium in the prostate as shown in previous studies [<xref rid="R13" ref-type="bibr">13</xref>]. Furthermore, it was demonstrated that after supplementation with 200 &#x003bc;g <italic>L</italic>-selenomethionine per day differences exist in gene expression profiles in human prostate tissue as compared to a placebo group [<xref rid="R14" ref-type="bibr">14</xref>]. Whether these differences in gene expression underlie possible chemopreventive properties is not clear, because <italic>L</italic>-selenomethionine itself did not show preventive effects for prostate cancer in the SELECT trial [<xref rid="R6" ref-type="bibr">6</xref>]. Other forms of selenium, such as selenized yeast, have been shown to be effective for the prevention of prostate cancer in a subgroup of participants with a low baseline selenium status [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>], however, detailed information on the molecular effects in prostate tissue is lacking.</p><p>The aim of the current study was to obtain more insight into the molecular pathways affected by selenium in the prostate. Therefore, we examined whole-genome expression profiles in non-malignant prostate tissue before and after a 5-week intervention with selenized yeast in a randomized, placebo-controlled trial in The Netherlands. The collection of prostate tissue before and after intervention allowed us to compare changes in gene expression within individuals over time.</p></sec><sec id="s2"><title>RESULTS</title><p>From June 2007 to October 2010, 281 men were assessed for their eligibility to participate in this study. Of these, 23 men were finally enrolled; 12 participants were randomized to the selenium group and 11 participants to the placebo group (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 1</xref>). Baseline characteristics of the participants are presented in Table <xref ref-type="table" rid="T1">1</xref>. The median duration of the intervention period was 35 days (interquartile range (IQR): 31; 35). Compliance, as assessed by pill count and inspection of research diaries, ranged from 94% to 100%.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Characteristics of the participants at baseline and after the intervention with selenium or placebo</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1"/><th rowspan="2" align="left" valign="middle" colspan="1">All</th><th colspan="2" align="left" valign="middle" rowspan="1">Participants who completed the intervention</th><th colspan="2" align="left" valign="middle" rowspan="1">Participants who were eligible for microarray analysis</th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">Placebo</th><th align="left" valign="middle" rowspan="1" colspan="1">Selenium</th><th align="left" valign="middle" rowspan="1" colspan="1">Placebo</th><th align="left" valign="middle" rowspan="1" colspan="1">Selenium</th></tr></thead><tbody><tr><td colspan="6" align="left" valign="middle" rowspan="1"><bold>Sociodemographic</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number of participants</td><td align="left" valign="middle" rowspan="1" colspan="1">23</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">12</td><td align="left" valign="middle" rowspan="1" colspan="1">7</td><td align="left" valign="middle" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age at start intervention (years)</td><td align="left" valign="middle" rowspan="1" colspan="1">67.5 (65.0-72.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">69.5 (63.0-72.6)</td><td align="left" valign="middle" rowspan="1" colspan="1">67.1 (65.2-71.2)</td><td align="left" valign="middle" rowspan="1" colspan="1">65.6 (61.9-73.1)</td><td align="left" valign="middle" rowspan="1" colspan="1">68.4 (65.2-71.9)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="left" valign="middle" rowspan="1" colspan="1">26.2 (24.2-28.1)</td><td align="left" valign="middle" rowspan="1" colspan="1">26.2 (24.7-28.5)</td><td align="left" valign="middle" rowspan="1" colspan="1">26.4 (23.8-28.0)</td><td align="left" valign="middle" rowspan="1" colspan="1">26.2 (24.7-28.5)</td><td align="left" valign="middle" rowspan="1" colspan="1">25.5 (23.5-27.8)</td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1">Smoking</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Current</td><td align="left" valign="middle" rowspan="1" colspan="1">4 (17%)</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (9%)</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (25%)</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (13%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Former</td><td align="left" valign="middle" rowspan="1" colspan="1">13 (57%)</td><td align="left" valign="middle" rowspan="1" colspan="1">6 (55%)</td><td align="left" valign="middle" rowspan="1" colspan="1">7 (67%)</td><td align="left" valign="middle" rowspan="1" colspan="1">5 (71%)</td><td align="left" valign="middle" rowspan="1" colspan="1">5 (63%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Never</td><td align="left" valign="middle" rowspan="1" colspan="1">6 (26%)</td><td align="left" valign="middle" rowspan="1" colspan="1">4 (36%)</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (8%)</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (29%)</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (25%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Use of dietary supplements (current)</td><td align="left" valign="middle" rowspan="1" colspan="1">7 (30%)</td><td align="left" valign="middle" rowspan="1" colspan="1">4 (36%)</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (25%)</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (29%)</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (25%)</td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1"><bold>Clinical</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Prediagnostic PSA levels (ng/mL)</td><td align="left" valign="middle" rowspan="1" colspan="1">8.0 (4.5-10.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">7.7 (3.8-11.0)</td><td align="left" valign="middle" rowspan="1" colspan="1">9.4 (6.0-10.2)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.0 (3.0-11.0)</td><td align="left" valign="middle" rowspan="1" colspan="1">9.6 (6.4-10.2)</td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1">Diagnosis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;No evidence of malignancy</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (4%)</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (8%)</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (13%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;HGPIN</td><td align="left" valign="middle" rowspan="1" colspan="1">5 (22%)</td><td align="left" valign="middle" rowspan="1" colspan="1">4 (36%)</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (8%)</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (43%)</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (13%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Prostate cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">17 (74%)</td><td align="left" valign="middle" rowspan="1" colspan="1">7 (64%)</td><td align="left" valign="middle" rowspan="1" colspan="1">10 (83%)</td><td align="left" valign="middle" rowspan="1" colspan="1">4 (57%)</td><td align="left" valign="middle" rowspan="1" colspan="1">6 (75%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gleason score at biopsy<sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x0003c;7</td><td align="left" valign="middle" rowspan="1" colspan="1">10 (59%)</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (43%)</td><td align="left" valign="middle" rowspan="1" colspan="1">7 (70%)</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (75%)</td><td align="left" valign="middle" rowspan="1" colspan="1">5 (83%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02265;7</td><td align="left" valign="middle" rowspan="1" colspan="1">7 (41%)</td><td align="left" valign="middle" rowspan="1" colspan="1">4 (57%)</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (30%)</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (25%)</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (17%)</td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1">Chronic inflammation at baseline<sup>b</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;No inflammation</td><td align="left" valign="middle" rowspan="1" colspan="1">8 (35%)</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (27%)</td><td align="left" valign="middle" rowspan="1" colspan="1">5 (42%)</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (29%)</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (25%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x0003c;10% of the study biopsy</td><td align="left" valign="middle" rowspan="1" colspan="1">13 (57%)</td><td align="left" valign="middle" rowspan="1" colspan="1">7 (64%)</td><td align="left" valign="middle" rowspan="1" colspan="1">6 (50%)</td><td align="left" valign="middle" rowspan="1" colspan="1">5 (71%)</td><td align="left" valign="middle" rowspan="1" colspan="1">5 (63%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;10-50% of the study biopsy</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (4%)</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (8%)</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (13%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Unknown</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (4%)</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (9%)</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1">Type of treatment / clinical follow-up</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Re-biopsy</td><td align="left" valign="middle" rowspan="1" colspan="1">9 (39%)</td><td align="left" valign="middle" rowspan="1" colspan="1">4 (36%)</td><td align="left" valign="middle" rowspan="1" colspan="1">5 (42%)</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (43%)</td><td align="left" valign="middle" rowspan="1" colspan="1">4 (50%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Radical prostatectomy</td><td align="left" valign="middle" rowspan="1" colspan="1">6 (26%)</td><td align="left" valign="middle" rowspan="1" colspan="1">4 (36%)</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (17%)</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (29%)</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Radiotherapy</td><td align="left" valign="middle" rowspan="1" colspan="1">8 (35%)</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (27%)</td><td align="left" valign="middle" rowspan="1" colspan="1">5 (42%)</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (29%)</td><td align="left" valign="middle" rowspan="1" colspan="1">4 (50%)</td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1"><bold>Intervention</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Duration of intervention period (days)</td><td align="left" valign="middle" rowspan="1" colspan="1">35 (31-35)</td><td align="left" valign="middle" rowspan="1" colspan="1">35 (34-35)</td><td align="left" valign="middle" rowspan="1" colspan="1">33 (28-35)</td><td align="left" valign="middle" rowspan="1" colspan="1">35 (34-35)</td><td align="left" valign="middle" rowspan="1" colspan="1">35 (32-35)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Time between collection of prostate tissue (days)</td><td align="left" valign="middle" rowspan="1" colspan="1">64 (35-98)</td><td align="left" valign="middle" rowspan="1" colspan="1">65 (36-98)</td><td align="left" valign="middle" rowspan="1" colspan="1">64 (33-96)</td><td align="left" valign="middle" rowspan="1" colspan="1">65 (36-112)</td><td align="left" valign="middle" rowspan="1" colspan="1">49 (32-96)</td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1"><bold>Selenium levels</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Toenail selenium (mg/kg)</td><td align="left" valign="middle" rowspan="1" colspan="1">at baseline</td><td align="left" valign="middle" rowspan="1" colspan="1">0.45 (0.37-0.50)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.43 (0.37-0.48)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.44 (0.37-0.48)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.42 (0.37-0.60)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Serum selenium levels (&#x003bc;mol/L)</td><td align="left" valign="middle" rowspan="1" colspan="1">at baseline</td><td align="left" valign="middle" rowspan="1" colspan="1">1.06 (0.92-1.18)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.00 (0.92-1.08)<sup>c</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">1.09 (1.04-1.18)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.06 (0.93-1.17)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">after intervention</td><td align="left" valign="middle" rowspan="1" colspan="1">1.11 (0.95-1.25)<sup>d</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">2.36 (1.74-2.98)<sup>c,e</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">1.12 (0.98-1.23)</td><td align="left" valign="middle" rowspan="1" colspan="1">2.82 (2.30-3.04)<sup>f</sup></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Only for participants with prostate cancer,</p><p><sup>b</sup>Chronic inflammation in the prostate biopsies was defined as infiltration of mononuclear cells at the periglandular stroma. The extent of inflammation was classified as affected volume (%) of the study biopsy.</p><p><sup>c</sup>One participant from the selenium group was excluded, because data on serum selenium levels at baseline and after intervention were not available,</p><p><sup>d</sup>One participant in the placebo group was excluded, because sample collection after the intervention failed.</p><p><sup>e</sup>Statistically significant if compared to baseline levels (p=0.004, Wilcoxon Signed Rank test).</p><p><sup>f</sup>Statistically significant if compared to baseline levels (p=0.012, Wilcoxon Signed Rank test).</p><p>Data presented as median (interquartile range) or numbers (%). Statistical tests were only performed for toenail and serum selenium levels.</p><p>Abbreviations: <italic>HGPIN</italic> high-grade prostatic intraepithelial neoplasia, <italic>PSA</italic> prostate specific antigen.</p></table-wrap-foot></table-wrap><sec id="s2_1"><title>Levels of selenium</title><p>Baseline levels of serum (p=0.562) or toenail (p=0.449) selenium did not differ between the two groups (Table <xref ref-type="table" rid="T1">1</xref>). As compared to baseline values, the serum selenium levels after intervention increased in the selenium group (median increase 1.44 &#x003bc;mol/L, IQR 0.66; 1.92, p=0.004), but not in the placebo group (median increase 0.02 &#x003bc;mol/L, IQR -0.04; 0.18, p=0.314).</p></sec><sec id="s2_2"><title>Microarray analyses</title><p>Good quality RNA from prostate biopsies from the transition zone without evidence of malignancy was available before and after the intervention for 15 participants, resulting in a total of 30 microarrays used in this study (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 1</xref>). After Robust Multichip Average (RMA) normalization and filtering, 18,437 genes were considered expressed and were included in further analyses (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 2</xref>). Comparisons between the selenium and placebo group showed that for 2765 genes pairwise expression changes (after intervention minus before intervention) differed (Limma p-value &#x0003c;0.05). Subsequent within-group comparisons of individual gene expression profiles before and after intervention revealed that of these 2765 genes, expression of 915 genes (524 down-regulated and 391 up-regulated) was changed in the selenium group. In the placebo group expression changes were observed for 1380 out of 2765 genes, of which 661 were down-regulated and 719 up-regulated (<xref rid="SD2" ref-type="supplementary-material">Supplementary Table 1</xref>). At baseline, differences in gene expression exist between the selenium and placebo group (n=2624 genes with Limma p-value &#x0003c;0.05).</p></sec><sec id="s2_3"><title>Biological pathway analyses</title><p>To obtain more insight into the role of the differentially expressed genes, pathway analyses were conducted. The top-5 regulated canonical pathways are presented for both the selenium and the placebo group in Figure <xref ref-type="fig" rid="F1">1</xref>. The intervention with selenium was associated with down-regulated expression of genes involved in signaling pathways related to inflammation, cellular immune response and cellular growth, proliferation and development. Opposite effects were observed in the placebo group with expression of genes involved in pathways related to cellular immune responses being up-regulated.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>The top-5 pathways, identified by IPA Canonical Pathway Analysis, which are most significantly regulated by the intervention with selenium (lower panel) or placebo (upper panel)</title><p>The numbers behind the pathways indicate the number of genes that belong to that pathway and the numbers behind the bars represent the number of differentially expressed genes within that pathway (these genes had a p-value of &#x0003c;0.05 in the within- and between-group comparisons). Significance of the pathways, as assessed by the Fisher&#x02019;s Exact test, is expressed by a (-log2) p-value.</p></caption><graphic xlink:href="oncotarget-08-10565-g001"/></fig><p>A gene set enrichment analysis (GSEA) was performed to explore the consistency of our findings for the selenium supplementation. Gene sets enriched in the selenium group are visualized in Figure <xref ref-type="fig" rid="F2">2</xref>. Two main clusters of gene sets were identified and were classified as A) wound healing, cellular adhesion and extracellular matrix interactions and B) inflammation and immunity. All of the gene sets in these two clusters were considered &#x02018;negative&#x02019; which implies that genes in these gene-sets were down-regulated after the intervention with selenium. Furthermore, expression of genes involved in cellular adhesion, inflammation, extracellular matrix interactions and chemokine signaling was down-regulated after intervention with selenium. For the placebo group, gene sets referring to inflammation, infection, hemostasis and cellular adhesion were enriched and considered &#x02018;positive&#x02019; after the intervention (data not presented), which again points towards the opposite effects on gene expression found after the intervention with selenium versus placebo.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Enrichment map of the Gene Set Enrichment Analysis (GSEA) reflecting the gene sets that are enriched after the intervention with selenium</title><p>The gene sets are presented according to clusters which were assigned a label based on their common function or annotation. The clusters are: <bold>A</bold>. wound healing, cellular adhesion and extracellular matrix interactions, <bold>B</bold>. inflammation and immunity, <bold>C</bold>. metabolism, <bold>D</bold>. muscle contraction, <bold>E</bold>. miscellaneous. Down-regulated gene sets are visualized as solid grey nodes, while up-regulated gene sets are white nodes with a grey border. Size of the nodes represents the number of genes involved. If there are overlapping genes between gene sets, the gene sets are connected through a line.</p></caption><graphic xlink:href="oncotarget-08-10565-g002"/></fig><p>Based on the IPA Upstream Regulator Analysis, we identified regulators that may have been responsible for the observed expression changes. Predicted upstream regulators were considered relevant if the z-score was below -2 or above 2 and if the p-value of overlap was &#x0003c;0.05. The top-5 (based on z-score) of the predicted activated and inhibited regulators is presented in Table <xref ref-type="table" rid="T2">2</xref>. Transforming growth factor &#x003b2;1 (<italic>TGFB1</italic>) was identified as an upstream regulator predicted to be inhibited in the selenium group and activated in the placebo group (p-value of overlap 3.70E-06 and 4.35E-12, respectively).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>The top-5 of the predicted activated and inhibited upstream regulators with the highest and lowest z-scores according to IPA Upstream Regulator Analysis</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="left" valign="middle" rowspan="1" colspan="1">Fold change after intervention</th><th align="left" valign="middle" rowspan="1" colspan="1">Molecule type</th><th align="left" valign="middle" rowspan="1" colspan="1">Predicted activation state</th><th align="left" valign="middle" rowspan="1" colspan="1">Activation z-score</th><th align="left" valign="middle" rowspan="1" colspan="1">p-value of overlap</th></tr></thead><tbody><tr><td colspan="6" align="left" valign="middle" rowspan="1"><bold>Selenium</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF</td><td align="left" valign="middle" rowspan="1" colspan="1">-1.1</td><td align="left" valign="middle" rowspan="1" colspan="1">cytokine</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibited</td><td align="left" valign="middle" rowspan="1" colspan="1">-3.85</td><td align="left" valign="middle" rowspan="1" colspan="1">1.94E-03</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PDGF BB</td><td align="left" valign="middle" rowspan="1" colspan="1">NA</td><td align="left" valign="middle" rowspan="1" colspan="1">complex</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibited</td><td align="left" valign="middle" rowspan="1" colspan="1">-2.56</td><td align="left" valign="middle" rowspan="1" colspan="1">3.39E-05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TP53</td><td align="left" valign="middle" rowspan="1" colspan="1">1.1</td><td align="left" valign="middle" rowspan="1" colspan="1">transcription regulator</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibited</td><td align="left" valign="middle" rowspan="1" colspan="1">-2.32</td><td align="left" valign="middle" rowspan="1" colspan="1">4.44E-03</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGFB1</td><td align="left" valign="middle" rowspan="1" colspan="1">-1.2</td><td align="left" valign="middle" rowspan="1" colspan="1">growth factor</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibited</td><td align="left" valign="middle" rowspan="1" colspan="1">-2.28</td><td align="left" valign="middle" rowspan="1" colspan="1">3.70E-06</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">STAT5a/b</td><td align="left" valign="middle" rowspan="1" colspan="1">NA</td><td align="left" valign="middle" rowspan="1" colspan="1">group</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibited</td><td align="left" valign="middle" rowspan="1" colspan="1">-2.24</td><td align="left" valign="middle" rowspan="1" colspan="1">1.93E-03</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TAB1</td><td align="left" valign="middle" rowspan="1" colspan="1">-1.0</td><td align="left" valign="middle" rowspan="1" colspan="1">enzyme</td><td align="left" valign="middle" rowspan="1" colspan="1">Activated</td><td align="left" valign="middle" rowspan="1" colspan="1">2.00</td><td align="left" valign="middle" rowspan="1" colspan="1">1.39E-02</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SPDEF</td><td align="left" valign="middle" rowspan="1" colspan="1">1.4</td><td align="left" valign="middle" rowspan="1" colspan="1">transcription regulator</td><td align="left" valign="middle" rowspan="1" colspan="1">Activated</td><td align="left" valign="middle" rowspan="1" colspan="1">2.16</td><td align="left" valign="middle" rowspan="1" colspan="1">3.97E-02</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAP3K7</td><td align="left" valign="middle" rowspan="1" colspan="1">-1.0</td><td align="left" valign="middle" rowspan="1" colspan="1">kinase</td><td align="left" valign="middle" rowspan="1" colspan="1">Activated</td><td align="left" valign="middle" rowspan="1" colspan="1">2.22</td><td align="left" valign="middle" rowspan="1" colspan="1">1.02E-02</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WISP2</td><td align="left" valign="middle" rowspan="1" colspan="1">-1.2</td><td align="left" valign="middle" rowspan="1" colspan="1">growth factor</td><td align="left" valign="middle" rowspan="1" colspan="1">Activated</td><td align="left" valign="middle" rowspan="1" colspan="1">2.45</td><td align="left" valign="middle" rowspan="1" colspan="1">3.16E-03</td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1"><bold>Placebo</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COL18A1</td><td align="left" valign="middle" rowspan="1" colspan="1">1.1</td><td align="left" valign="middle" rowspan="1" colspan="1">other</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibited</td><td align="left" valign="middle" rowspan="1" colspan="1">-3.77</td><td align="left" valign="middle" rowspan="1" colspan="1">1.94E-07</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SPDEF</td><td align="left" valign="middle" rowspan="1" colspan="1">-1.3</td><td align="left" valign="middle" rowspan="1" colspan="1">transcription regulator</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibited</td><td align="left" valign="middle" rowspan="1" colspan="1">-2.95</td><td align="left" valign="middle" rowspan="1" colspan="1">3.75E-04</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NEUROG1</td><td align="left" valign="middle" rowspan="1" colspan="1">-1.0</td><td align="left" valign="middle" rowspan="1" colspan="1">enzyme</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibited</td><td align="left" valign="middle" rowspan="1" colspan="1">-2.83</td><td align="left" valign="middle" rowspan="1" colspan="1">3.85E-08</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">JAG2</td><td align="left" valign="middle" rowspan="1" colspan="1">1.1</td><td align="left" valign="middle" rowspan="1" colspan="1">complex</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibited</td><td align="left" valign="middle" rowspan="1" colspan="1">-2.45</td><td align="left" valign="middle" rowspan="1" colspan="1">1.30E-02</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL1RN</td><td align="left" valign="middle" rowspan="1" colspan="1">1.2</td><td align="left" valign="middle" rowspan="1" colspan="1">transcription regulator</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibited</td><td align="left" valign="middle" rowspan="1" colspan="1">-2.38</td><td align="left" valign="middle" rowspan="1" colspan="1">1.66E-03</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IFNG</td><td align="left" valign="middle" rowspan="1" colspan="1">NA</td><td align="left" valign="middle" rowspan="1" colspan="1">cytokine</td><td align="left" valign="middle" rowspan="1" colspan="1">Activated</td><td align="left" valign="middle" rowspan="1" colspan="1">4.89</td><td align="left" valign="middle" rowspan="1" colspan="1">1.03E-12</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PDGF BB</td><td align="left" valign="middle" rowspan="1" colspan="1">NA</td><td align="left" valign="middle" rowspan="1" colspan="1">complex</td><td align="left" valign="middle" rowspan="1" colspan="1">Activated</td><td align="left" valign="middle" rowspan="1" colspan="1">5.48</td><td align="left" valign="middle" rowspan="1" colspan="1">9.59E-20</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGFB1</td><td align="left" valign="middle" rowspan="1" colspan="1">1.3</td><td align="left" valign="middle" rowspan="1" colspan="1">growth factor</td><td align="left" valign="middle" rowspan="1" colspan="1">Activated</td><td align="left" valign="middle" rowspan="1" colspan="1">5.70</td><td align="left" valign="middle" rowspan="1" colspan="1">4.35E-12</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGM2</td><td align="left" valign="middle" rowspan="1" colspan="1">1.8</td><td align="left" valign="middle" rowspan="1" colspan="1">enzyme</td><td align="left" valign="middle" rowspan="1" colspan="1">Activated</td><td align="left" valign="middle" rowspan="1" colspan="1">6.10</td><td align="left" valign="middle" rowspan="1" colspan="1">2.79E-09</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF</td><td align="left" valign="middle" rowspan="1" colspan="1">1.1</td><td align="left" valign="middle" rowspan="1" colspan="1">cytokine</td><td align="left" valign="middle" rowspan="1" colspan="1">Activated</td><td align="left" valign="middle" rowspan="1" colspan="1">6.94</td><td align="left" valign="middle" rowspan="1" colspan="1">7.97E-29</td></tr></tbody></table><table-wrap-foot><p>For calculation of the z-score IPA included information about the up- or down-regulated status of the genes in the dataset. For this analysis, the expression of genes was considered up- or down-regulated if the p-value for the within (after intervention versus baseline) and between group (changes in selenium versus placebo) comparisons was below p&#x0003c;0.05. Upstream regulators in the top-5 of the highest and lowest z-scores are only presented if their p-value of overlap was below 0.05.</p><p>Abbreviations: <italic>IPA</italic> Ingenuity Pathway Analysis, NA not available</p></table-wrap-foot></table-wrap><p>Focusing on the network of <italic>TGFB1</italic> and a selection of other predicted upstream regulators in the selenium group, i.e. the SAM pointed domain containing ETS transcription factor (<italic>SPDEF</italic>) and WNT1 inducible signaling pathway protein 2 (<italic>WISP2</italic>), showed some common targets that are directly or indirectly controlled by these regulators (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 3</xref>). Vimentin (<italic>VIM</italic>), E-cadherin (<italic>CDH1</italic>), OB-cadherin (<italic>CDH11</italic>) and connective tissue growth factor (<italic>CTGF</italic>) are all considered to be regulated by <italic>TGFB1</italic>, <italic>SPDEF</italic> and <italic>WISP2</italic>. Interestingly, both <italic>TGFB1</italic> as well as the down-stream genes <italic>CDH1</italic>, <italic>CDH11</italic>, <italic>VIM</italic> and <italic>CTGF</italic> are suggested to be involved in the epithelial-to-mesenchymal transition (EMT). EMT is a process characterized by the transition of an epithelial phenotype towards a mesenchymal phenotype and is implicated in embryogenesis, inflammation, wound healing, as well as cancer progression and metastasis.</p><p>Based on literature [<xref rid="R15" ref-type="bibr">15</xref>], we obtained an EMT-core gene list of 130 genes that are implicated in EMT and cancer progression. Gene expression changes after intervention for all our participants were plotted amongst this EMT-core list (Figure <xref ref-type="fig" rid="F3">3</xref>). Overall, the intervention with selenium resulted in down-regulated expression of genes known to be up-regulated during EMT. More specifically, expression of the &#x02018;mesenchymal markers&#x02019; <italic>FN1</italic> (fibronectin), <italic>VIM</italic>, and <italic>CDH11</italic> was down-regulated, while &#x02018;epithelial markers&#x02019;, such as <italic>CDH1</italic>, <italic>SDC1</italic> (syndecan-1) and <italic>EPCAM</italic> (epithelial cell adhesion molecule), were up-regulated after intervention with selenium.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Heatmap of the individual gene expression changes of 130 EMT-core genes in participants receiving selenium or placebo</title><p>According to literature [reference <xref rid="R15" ref-type="bibr">15</xref>], <bold>panel A</bold> represent genes that are up-regulated during EMT, while <bold>panel B</bold> includes genes that are down-regulated during EMT. Changes in gene expression are presented as signal-log-ratios (green; SLR &#x02264; -0.5 to red; SLR &#x02265; 0.5). For genes with bold names, the expression changed after the intervention with selenium (Limma p-value &#x0003c;0.05). Underlined genes had expression changes that are significantly different between the selenium and placebo group (Limma p-value &#x0003c;0.05). Abbreviations: <italic>EMT</italic> epithelial-to-mesenchymal transition, <italic>SLR</italic> Signal-Log-Ratio.</p></caption><graphic xlink:href="oncotarget-08-10565-g003"/></fig><p>In order to explore the consistency and robustness of our findings, we correlated the selenium-induced expression changes of all statistically significant (in within-, and between-group comparisons) EMT-related genes amongst each other. The corresponding Pearson correlation matrix for selenium (Figure <xref ref-type="fig" rid="F4">4</xref>) showed that expression changes of genes that are known to be up-regulated during EMT (i.e. mesenchymal markers) were inversely correlated to the expression changes of genes down-regulated during EMT (i.e. epithelial markers). A simplified hypothetical model for the suggested effects of selenium on EMT in the prostate is presented in Figure <xref ref-type="fig" rid="F5">5</xref>.</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>Correlation matrix showing the correlations between the expression changes for genes involved in epithelial-to-mesenchymal transition (EMT)</title><p>Calculation of the Pearson correlation coefficient is based on the individual signal-log-ratios representing the expression changes after the intervention with selenium. Only genes from the EMT-core [<xref rid="R15" ref-type="bibr">15</xref>] list for which the expression changed after the intervention with selenium and differed from the placebo group (Limma p-value &#x0003c;0.05) are presented. Green legends besides the genes indicate that these genes are commonly down-regulated during EMT, while genes presented in red are commonly up-regulated during EMT [<xref rid="R15" ref-type="bibr">15</xref>].</p></caption><graphic xlink:href="oncotarget-08-10565-g004"/></fig><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>Simplified hypothetical model for the suggested effects of selenium on epithelial-to-mesenchymal transition in prostate tissue</title><p>Abbreviations: <italic>EPCAM</italic> epithelial cell adhesion molecule, <italic>EMT</italic> epithelial-to-mesenchymal transition, <italic>MET</italic> mesenchymal-to-epithelial transition, <italic>SPDEF</italic> SAM pointed domain containing ETS transcription factor, <italic>TGFb</italic> transforming growth factor beta.</p></caption><graphic xlink:href="oncotarget-08-10565-g005"/></fig></sec></sec><sec id="s3"><title>DISCUSSION</title><p>Our study demonstrated that a 5-week intervention with selenium was associated with changes in expression of genes implicated in EMT in non-malignant prostate tissue. EMT is characterized by the transition of an epithelial towards mesenchymal phenotype with its accompanying properties such as the ability to migrate and invade [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R17" ref-type="bibr">17</xref>]. Based on our findings, we hypothesized that selenium may be able to prevent, inhibit or reverse the transition of the epithelial to the mesenchymal phenotype. Expression of numerous well-established epithelial cell markers was increased, while expression of mesenchymal markers was decreased after intervention with selenium. The observation that expression changes for epithelial versus mesenchymal markers were inversely correlated implies that our findings were consistent and were not likely resulting from chance findings.</p><p>EMT plays an important role during embryogenesis, inflammation and wound healing as cellular migration and invasion facilitates organ development, tissue (re)modelling and regeneration [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>]. In parallel with the reported expression changes for genes implicated in EMT, expression of genes involved in these processes was affected after the intervention with selenium as well. A possible, but speculative, explanation for the pronounced inflammatory gene expression profile observed in the placebo group may be a persisting inflammatory response resulting from the first series of prostate biopsies. Interestingly, this inflammatory expression profile was not observed in the selenium group, which points towards a possible anti-inflammatory effect of selenium in the prostate. It should be noted that the median, but not mean, time between the repeated collection of prostate biopsies tended to be slightly shorter for participants in the selenium versus placebo group. The time between the biopsies for the individual participants was [32, 32, 32, 35, 63, 91, 98, 112 days] for the selenium group and [35, 36, 63, 65, 72, 112, 112 days] for the placebo group, which did not reveal any systematic differences between the groups.</p><p>The intervention with selenium was also associated with expression changes of genes involved in wound healing, cellular adhesion and extracellular matrix interactions. Based on our GSEA results, we identified a cluster of gene sets related to wound healing which were down-regulated after the intervention with selenium. The pronounced effects hinting towards wound healing in the placebo group may again refer to repair and remodeling of prostate tissue resulting from the (repeated) biopsies. Interestingly, in the selenium group expression of genes involved in wound healing was down-regulated. Based upon these data, we carefully hypothesized that selenium may contribute to accelerated or improved wound healing in the prostate.</p><p>So far, the role of selenium in wound healing has not been extensively described. Few small clinical studies or animal experiments suggest that selenium may improve and accelerate wound healing under various conditions [<xref rid="R19" ref-type="bibr">19</xref>, <xref rid="R20" ref-type="bibr">20</xref>]. One of the potential key players implicated in wound healing is the gap junction protein connexin43 (Cx43) encoded by the <italic>GAJ1</italic> gene [<xref rid="R21" ref-type="bibr">21</xref>]. Experimental down-regulation of Cx43 at wound sites resulted in an improved rate and quality of healing [<xref rid="R22" ref-type="bibr">22</xref>]. Our intervention with selenium was also associated with down-regulated expression of <italic>GAJ1</italic>/Cx43 as well as <italic>GJC1</italic>/Cx45, whereas in the placebo group the expression of these connexins did not change. Interestingly, increased expression of <italic>GAJ1</italic>/Cx43 has also been linked to metastatic behavior of prostate cancer cells [<xref rid="R23" ref-type="bibr">23</xref>, <xref rid="R24" ref-type="bibr">24</xref>].</p><p>The potential mechanisms underlying the effect of selenium on EMT, with or without a direct relationship to wound healing and inflammation, have not been described in detail previously. It has consistently been shown that transforming growth factor &#x003b2;1 (<italic>TGFB1</italic>) is a major inducer of EMT [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R25" ref-type="bibr">25</xref>] and is also involved in inflammation and wound healing [<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R26" ref-type="bibr">26</xref>]. In our study, the expression of <italic>TGFB1</italic> is significantly down-regulated after the intervention with selenium, while up-regulated in the placebo group. <italic>TGFB1</italic> was also one of the main predicted upstream transcriptional regulators. Changes in protein expression of TGFbeta in serum of elderly men after selenium supplementation have been previously described [<xref rid="R27" ref-type="bibr">27</xref>].</p><p>We also identified the sterile alpha motif (SAM) pointed domain-containing ETS transcription factor (<italic>SPDEF</italic>) as an upstream transcriptional regulator. <italic>SPDEF</italic> is highly expressed in normal prostatic epithelial tissue [<xref rid="R28" ref-type="bibr">28</xref>, <xref rid="R29" ref-type="bibr">29</xref>]. Previous studies showed that <italic>SPDEF</italic> is required for <italic>CDH1</italic> expression in prostate cancer cells [<xref rid="R30" ref-type="bibr">30</xref>] and that <italic>SPDEF</italic> is a downstream target of <italic>TGFB1</italic> [<xref rid="R31" ref-type="bibr">31</xref>]. Our intervention with selenium was associated with increased <italic>SPDEF</italic> expression which is in line with the epithelial phenotype and the increase in <italic>CDH1</italic> expression. In previous studies, it was consistently shown that SPDEF inhibits cancer cell migration <italic>in vitro</italic> [<xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R32" ref-type="bibr">32</xref>] as well as prostate cancer metastasis <italic>in vivo</italic> [<xref rid="R33" ref-type="bibr">33</xref>]. Loss of SPDEF was associated with occurrence of aggressive high-grade prostate cancer [<xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R34" ref-type="bibr">34</xref>]. Methylseleninic acid (MSA), a synthetic selenium compound, has been shown to induce expression of <italic>SPDEF</italic> in prostate cancer cells [<xref rid="R34" ref-type="bibr">34</xref>], which is in line with the findings of our study.</p><p>To the best of our knowledge, the direct role of selenium in the regulation of EMT and related processes in the prostate has not been described in detail before. From <italic>in vitro</italic> work, it is known that the effects of selenium on EMT-related gene expression as well as migratory capacity strongly depend on the selenium compound used, the experimental conditions and the cell types or tissues studied [<xref rid="R35" ref-type="bibr">35</xref>&#x02013;<xref rid="R40" ref-type="bibr">40</xref>]. Data from human studies assessing the effects of selenium on gene expression profiles in prostate tissue are scarce. Tsavachidou and colleagues examined gene expression in distinct anatomical zones and cell types of the prostate after a 3-6 week intervention with <italic>L</italic>-selenomethionine [<xref rid="R14" ref-type="bibr">14</xref>]. Prostate tissue was collected at a single time point after the intervention period [<xref rid="R14" ref-type="bibr">14</xref>]. We collected prostate tissue before and after intervention, which allowed us to compare changes in gene expression within individuals. This aspect can be considered a major strength of our study, because variation due to inter-individual differences did not hinder the interpretation of the microarray data. Furthermore, due to the repeated sample collection, we were able to detect changes in gene expression that may not be directly attributed to the intervention with selenium, such as responses to the biopsy or other clinical procedures.</p><p>The marginal baseline selenium status of the participants may also be considered a strength of our study. In the NPC trial, specifically the participants with relatively low selenium status at baseline (selenium &#x0003c;123.2 &#x003bc;g/L) seemed to benefit from the intervention with selenized yeast [<xref rid="R2" ref-type="bibr">2</xref>]. Baseline selenium levels of the participants of the SELECT trial were relatively high (median 135 &#x003bc;g/L) [<xref rid="R6" ref-type="bibr">6</xref>]. The median selenium level of our participants was 81 &#x003bc;g/L and increased to 185 &#x003bc;g/L after the intervention. Based on experimental studies in dogs and a number of observational studies in humans, a U-shaped dose response curve for selenium status and several health outcomes was suggested [<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R41" ref-type="bibr">41</xref>, <xref rid="R42" ref-type="bibr">42</xref>]. While overlaying the U-shaped dose response curve with our data, it seemed that our participants started with a &#x02018;low status&#x02019; and ended with an &#x02018;optimal to high selenium status&#x02019;. One should, however, carefully interpret these findings, since it is not possible to draw conclusions about beneficial health effects of selenium in the current setting. Furthermore, it should be mentioned that the optimal range of selenium intake and status is narrow and strongly depends on various factors such as intake of various selenium compounds [<xref rid="R43" ref-type="bibr">43</xref>], genotype [<xref rid="R44" ref-type="bibr">44</xref>, <xref rid="R45" ref-type="bibr">45</xref>], and metabolic capacity [<xref rid="R10" ref-type="bibr">10</xref>].</p><p>A limitation of our study refers to the relatively small number of participants. Recruitment of participants was complicated inherent to the design of our study which required prostate sample collection at two consecutive time points and the unanticipated negative outcome of the SELECT trial. To what extent sample size affects the power to detect gene expression changes is difficult to assess for these data-driven expression profiling studies. At baseline, differences in gene expression exist between the selenium and placebo group (n=2624 genes), which may be attributable to unanticipated variation or outliers and the relatively small sample size. A subset of these genes was also differently expressed upon the intervention with selenium (n=437 genes, 17%). We cannot exclude the possibility that these baseline differences to some extent affected the responses observed. However, despite substantial variation and differences between the groups at baseline, gene expression changes were highly consistent within the groups after intervention. Furthermore, we examined effects of selenium supplementation at a transcriptional level and therefore we cannot rule out any potential post-transcriptional effects that may determine activity and functionality of other potential regulators, such as the selenoproteins.</p><p>For the current study, we collected non-malignant tissue from the transition zone of the prostate. Approximately 20% of the prostatic adenocarcinomas arise from this zone, in comparison to 70-80% from the peripheral zone [<xref rid="R46" ref-type="bibr">46</xref>]. The transition zone and the peripheral zones have been shown to differ in gene expression profiles [<xref rid="R46" ref-type="bibr">46</xref>], which may have consequences for the functional implications of our findings in other zones of the prostate. Limited amounts of tissue and common clinical practices precluded the assessment of selenium levels in the prostate or serum PSA levels after intervention, respectively. Other studies, however, have already shown that short-term (2-6 weeks) supplementation with selenized yeast or L-selenomethionine resulted in increased levels of selenium in the prostate [<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R48" ref-type="bibr">48</xref>].</p><p>In conclusion, our explorative data imply that selenium is associated with the regulation of genes involved in cellular migration, invasion, tissue remodeling and the immune response in non-malignant tissue collected from the transition zone of the prostate. These processes are implicated in EMT and related events such as inflammation, wound healing and cancer progression. Taken altogether, these results suggest a preventive effect of selenium on prostate cancer progression rather than on prostate cancer development and future studies are warranted to confirm this hypothesis.</p></sec><sec sec-type="methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Participants and design of the study</title><p>For this study, we collected non-malignant prostate tissue before and after a short-term intervention with selenized yeast or yeast placebo. We recruited participants from the Radboud university medical center, an academic tertiary referral center in Nijmegen, The Netherlands. Men scheduled for diagnostic prostate biopsies, and subsequent treatment with radical prostatectomy (RP) or radiotherapy (RT) for prostate cancer, were invited for this study. Also, men scheduled for re-biopsies because of high-grade prostatic intraepithelial neoplasia (HGPIN) were eligible for inclusion. For practical and ethical reasons, the men included in this study were all at high risk for prostate cancer or diagnosed with prostate cancer, as collection of prostate tissue for the study had to be combined with standard invasive clinical procedures. However, for all participants only non-malignant prostate tissue, verified by histological examinations, was considered for the analyses.</p><p>Exclusion criteria were current use of dietary supplements providing more than the recommended daily allowance of 55 &#x003bc;g selenium per day, any malignancy in the preceding five years (except for non-melanoma skin cancer), current hepatic or renal disease or inflammatory bowel disease, and neo-adjuvant therapies for prostate cancer.</p><p>Overall, 23 participants were eligible for participation in the intervention study (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 1</xref>). Before start of the intervention, prostate tissue, blood samples and toenail clippings were collected and body weight and height were measured. Furthermore, participants filled out a baseline questionnaire on sociodemographic characteristics, medical history and use of dietary supplements.</p></sec><sec id="s4_2"><title>Intervention</title><p>Participants were randomly assigned using a permuted-block design (blocks of four participants) to take 300 &#x003bc;g selenium per day in the form of selenized yeast (SelenoPrecise&#x000ae;, Pharma Nord, Denmark) or a placebo (non-selenized yeast, Pharma Nord, Denmark). The non-selenized yeast tablets were based on yeast grown on selenium-deficient medium and smell, taste and appearance did not differ from the intervention tablets. Both intervention and placebo tablets were previously used in the PRECISE Trial pilot studies [<xref rid="R49" ref-type="bibr">49</xref>&#x02013;<xref rid="R51" ref-type="bibr">51</xref>] and have been shown to have a stable batch-to-batch profile with L-selenomethionine (&#x0223c;81%) as the most abundant selenium compound in the intervention tablets [<xref rid="R51" ref-type="bibr">51</xref>, <xref rid="R52" ref-type="bibr">52</xref>]. Compliance was assessed by checking research diaries, counting returned tablets and measuring serum selenium levels before and after intervention. The intervention period had an intended duration of five weeks and was depending on the time between enrollment and final treatment or re-biopsy. The intervention period of five weeks was chosen because this resembles the average time between diagnostic biopsies and treatment by RP. During the intervention period, participants were asked to take daily supplements with selenium or placebo. At the end of the intervention period, prostate tissue and blood samples were collected for 22 participants. Sample collection for one participant failed because of logistic reasons. All participants returned remaining pills and their completed research diaries in which details concerning the use of study supplements were registered. The institutional review board (CMO Regio Arnhem-Nijmegen) approved the design of the study and all participants provided written informed consent. The trial was registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> with identifier NCT00446901.</p></sec><sec id="s4_3"><title>Selenium analyses</title><p>For serum selenium analyses, blood was collected into 10-ml serum tubes (Becton Dickinson B.V.). Serum was collected after centrifugation and stored at -20&#x000b0;C until analyses. Serum selenium levels were measured using an atomic absorption spectrometer (model 4100ZL, PerkinElmer) coupled with a graphite furnace and using Zeeman background correction [<xref rid="R53" ref-type="bibr">53</xref>]. The detection limit for this method was 0.10 &#x003bc;mol/L. For each analytical run, a series of standards (CertiPur&#x000ae; AAS standards, no. 1197960100, Merck Chemicals, Germany) and a control (Pathonorm-High<sup>TM</sup>, SERO AS, Norway) were included. All samples were analyzed in triplicate.</p><p>Baseline toenail selenium levels, indicative of a long-term selenium intake and status [<xref rid="R54" ref-type="bibr">54</xref>], were assessed using Instrumental Neutron Activation Analyses (INAA) at the Reactor Institute of Delft University, the Netherlands, as described previously [<xref rid="R55" ref-type="bibr">55</xref>].</p></sec><sec id="s4_4"><title>Collection of prostate tissue</title><p>Prostate tissue was collected using an 18-gauge biopsy needle (Bard Biopsy Systems) during regular 10-core prostate needle biopsy series guided by transrectal ultrasound (TRUS) or with a biopsy during RP. In both cases, the study biopsy was taken from the superior, ventral region of the left lobe of the prostate, which is specified as the transition zone. The study biopsy was directly embedded in Optimal Cutting Temperature (O.C.T.) Compound (Sakura Finetek Europe B.V.) and snapfrozen in liquid nitrogen. All samples were stored at -80&#x000b0;C.</p></sec><sec id="s4_5"><title>Histology</title><p>The biopsies embedded in O.C.T. Compound were sectioned at -20&#x000b0;C. Representative sections of 5 &#x003bc;m were used for histological examinations; at least two sections were used for a Haematoxilin-Eosin (HE) staining. The remainder of the biopsy was sectioned at 20 &#x003bc;m and used for RNA extraction. All HE-stained slides were reviewed for malignancy, HGPIN and inflammation by an expert uropathologist.</p></sec><sec id="s4_6"><title>RNA extraction</title><p>Total RNA was extracted from the sectioned prostate biopsies using TRIzol Reagent according to the manufacturer&#x02019;s instructions (Invitrogen). Isolated RNA was purified using RNeasy Micro columns (Qiagen). RNA integrity (RNA 6000 Nanochips for the Agilent 2100 Bioanalyzer, Agilent Technologies) and total RNA yield (Nanodrop ND 1000, Nanodrop Products) were assessed for all samples. The mean RNA integrity (RIN) score was 8.2 (standard deviation: 0.66). Prostate biopsies with inadequate RNA yield (&#x0003c;20 ng/&#x003bc;l, n=1) or histological evidence of adenocarcinoma (n=6) were excluded, leaving biopsies of 15 participants available for microarray analyses (n=8 selenium, n=7 placebo) (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 1</xref>).</p></sec><sec id="s4_7"><title>Microarray analyses</title><p>A total of 30 RNA samples were processed for microarray analyses. Briefly, 100 ng of total RNA per sample was converted to cDNA, labeled using an Ambion WT Expression kit and hybridized to Affymetrix GeneChip Human Gene 1.0 ST Arrays. Probe sets were redefined according to Dai et al. [<xref rid="R56" ref-type="bibr">56</xref>] using the remapped chip description files (CDF) version 14.1.1 based on the Entrez Gene database. The normalized signal intensities were expressed as Robust Multichip Average (RMA) expression values [<xref rid="R57" ref-type="bibr">57</xref>]. Genes with RMA expression values &#x0003e;20 in at least 4 arrays were considered as expressed in prostate tissue and were selected for further analyses. Ratios of the log(base2) transformed intensity signals (signal-log-ratios, SLR) were used to compare the individual microarray data before and after the intervention. Changes in gene expression within each of the groups were considered statistically significant if the p-value derived from the linear model (Limma: Linear Models for Microarray Data) [<xref rid="R58" ref-type="bibr">58</xref>] with pairwise comparisons and empirical Bayesian correction was &#x0003c;0.05. Differentially changed genes between the two groups were also identified using the Limma models with Bayesian correction (Limma p-value &#x0003c;0.05). Microarray data are available from the Gene Expression Omnibus (GEO) repository with accession number GSE77959.</p></sec><sec id="s4_8"><title>Biological pathway analyses</title><p>Regulated pathways were identified through the use of IPA (version 18030641, Ingenuity&#x000ae; Systems, <ext-link ext-link-type="uri" xlink:href="http://www.ingenuity.com">www.ingenuity.com</ext-link>). For these analyses, expression of genes was considered up- or down-regulated if the p-value for the within- and between-group comparisons was &#x0003c;0.05. Canonical pathways with a p-value of &#x0003c;0.01 in the Fisher&#x02019;s exact test were considered as significant to the data. IPA Upstream Regulator Analysis was used to predict common regulators that may be responsible for the observed changes in gene expression. Prediction of regulators is based on two parameters; the z-score and the p-value of overlap. The z-score reflects the consistency of the gene expression patterns of the downstream genes in the dataset, whereas the p-value of overlap is calculated by a Fisher&#x02019;s exact test for the overlap between the genes in a dataset (expected) and the genes actually regulated by the potential transcriptional regulator (observed).</p><p>In order to further explore the biological relevance and consistency of our findings, we also conducted Gene Set Enrichment Analyses (GSEA, <ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsea/index.jsp">http://www.broadinstitute.org/gsea/index.jsp</ext-link>) [<xref rid="R59" ref-type="bibr">59</xref>] for the changes in gene expression after the intervention with either selenium or placebo. Cytoscape 2.8.2 [<xref rid="R60" ref-type="bibr">60</xref>] was used to visualize the GSEA results in an enrichment map [<xref rid="R61" ref-type="bibr">61</xref>]. Gene sets with a False Discovery Rate (FDR) q-value of &#x0003c;0.01 were considered enriched to the data.</p><p>Gitools software was used to construct a correlation matrice showing the Pearson correlation coefficients for the individual expression changes expressed as signal-log-ratios of selected genes [<xref rid="R62" ref-type="bibr">62</xref>].</p></sec><sec id="s4_9"><title>Statistical analysis</title><p>Since levels of selenium after intervention, duration of intervention and a number of other participants&#x02019; characteristics were not normally distributed, data were summarized as median and interquartile ranges or numbers and percentages. Baseline serum and toenail selenium levels were compared between the selenium group and the placebo group using the Mann-Whitney U test. Serum selenium levels after intervention were compared to baseline values using the Wilcoxon Signed Rank test. All statistical tests were two-sided and p-values below &#x0003c;0.05 were considered as statistically significant. Statistical Package for Social Sciences (SPSS version 19, Chicago, Illinois) was used for all analyses unless otherwise stated.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>SUPPLEMENTARY MATERIALS FIGURES AND TABLES</title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-08-10565-s001.pdf" orientation="portrait" xlink:type="simple" id="d35e1618" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><media mimetype="application" mime-subtype="docx" xlink:href="oncotarget-08-10565-s002.docx" orientation="portrait" xlink:type="simple" id="d35e1620" position="anchor"/></supplementary-material></sec></body><back><ack><p>All participants are gratefully acknowledged for their participation in this study. Mechteld Grootte Bromhaar and Anita Bruggink-Hoopman are acknowledged for their assistance with sample collection and technical procedures. We wish to thank Guido Hooiveld, Mark Boekschoten and Philip de Groot for their help in gene expression analyses. We would like to thank Pharma Nord (Vejle, Denmark) for kindly providing the supplements (selenium and placebo) for this study.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>The authors declare no conflicts of interest.</p></fn><fn fn-type="supported-by"><p><bold>GRANT SUPPORT</bold></p><p>This project and D.E.G. Kok were funded by a research grant from the World Cancer Research Fund (WCRF) International, WCRF UK and WCRF NL (WCRF 2005/63). E. Kampman was supported by a research grant (2011-5234) from the Alpe d&#x02019;Huzes/Dutch Cancer Society.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>LC</given-names></name><name><surname>Combs</surname><given-names>GF</given-names><suffix>Jr.</suffix></name><name><surname>Turnbull</surname><given-names>BW</given-names></name><name><surname>Slate</surname><given-names>EH</given-names></name><name><surname>Chalker</surname><given-names>DK</given-names></name><name><surname>Chow</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>LS</given-names></name><name><surname>Glover</surname><given-names>RA</given-names></name><name><surname>Graham</surname><given-names>GF</given-names></name><name><surname>Gross</surname><given-names>EG</given-names></name><name><surname>Krongrad</surname><given-names>A</given-names></name><name><surname>Lesher</surname><given-names>JL</given-names><suffix>Jr.</suffix></name><name><surname>Park</surname><given-names>HK</given-names></name><name><surname>Sanders</surname><given-names>BB</given-names><suffix>Jr.</suffix></name><name><surname>Smith</surname><given-names>CL</given-names></name><name><surname>Taylor</surname><given-names>JR</given-names></name></person-group><article-title>Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group</article-title><source>JAMA</source><year>1996</year><volume>276</volume><fpage>1957</fpage><lpage>1963</lpage><pub-id pub-id-type="pmid">8971064</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffield-Lillico</surname><given-names>AJ</given-names></name><name><surname>Dalkin</surname><given-names>BL</given-names></name><name><surname>Reid</surname><given-names>ME</given-names></name><name><surname>Turnbull</surname><given-names>BW</given-names></name><name><surname>Slate</surname><given-names>EH</given-names></name><name><surname>Jacobs</surname><given-names>ET</given-names></name><name><surname>Marshall</surname><given-names>JR</given-names></name><name><surname>Clark</surname><given-names>LC</given-names></name></person-group><article-title>Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial</article-title><source>BJU Int</source><year>2003</year><volume>91</volume><fpage>608</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">12699469</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>DW</given-names></name><name><surname>Coleman</surname><given-names>IM</given-names></name><name><surname>Hawley</surname><given-names>S</given-names></name><name><surname>Dumpit</surname><given-names>R</given-names></name><name><surname>Gifford</surname><given-names>D</given-names></name><name><surname>Kezele</surname><given-names>P</given-names></name><name><surname>Hung</surname><given-names>H</given-names></name><name><surname>Knudsen</surname><given-names>BS</given-names></name><name><surname>Kristal</surname><given-names>AR</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name></person-group><article-title>Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>3763</fpage><lpage>3770</lpage><pub-id pub-id-type="pmid">16822846</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Fan</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name></person-group><article-title>Selenium Exposure and Cancer Risk: an Updated Meta-analysis and Meta-regression</article-title><source>Scientific reports</source><year>2016</year><volume>6</volume><fpage>19213</fpage><pub-id pub-id-type="pmid">26786590</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>NE</given-names></name><name><surname>Appleby</surname><given-names>PN</given-names></name><name><surname>Roddam</surname><given-names>AW</given-names></name><name><surname>Tjonneland</surname><given-names>A</given-names></name><name><surname>Johnsen</surname><given-names>NF</given-names></name><name><surname>Overvad</surname><given-names>K</given-names></name><name><surname>Boeing</surname><given-names>H</given-names></name><name><surname>Weikert</surname><given-names>S</given-names></name><name><surname>Kaaks</surname><given-names>R</given-names></name><name><surname>Linseisen</surname><given-names>J</given-names></name><name><surname>Trichopoulou</surname><given-names>A</given-names></name><name><surname>Misirli</surname><given-names>G</given-names></name><name><surname>Trichopoulos</surname><given-names>D</given-names></name><name><surname>Sacerdote</surname><given-names>C</given-names></name><name><surname>Grioni</surname><given-names>S</given-names></name><name><surname>Palli</surname><given-names>D</given-names></name><etal/></person-group><article-title>Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>88</volume><fpage>1567</fpage><lpage>1575</lpage><pub-id pub-id-type="pmid">19064517</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippman</surname><given-names>SM</given-names></name><name><surname>Klein</surname><given-names>EA</given-names></name><name><surname>Goodman</surname><given-names>PJ</given-names></name><name><surname>Lucia</surname><given-names>MS</given-names></name><name><surname>Thompson</surname><given-names>IM</given-names></name><name><surname>Ford</surname><given-names>LG</given-names></name><name><surname>Parnes</surname><given-names>HL</given-names></name><name><surname>Minasian</surname><given-names>LM</given-names></name><name><surname>Gaziano</surname><given-names>JM</given-names></name><name><surname>Hartline</surname><given-names>JA</given-names></name><name><surname>Parsons</surname><given-names>JK</given-names></name><name><surname>Bearden</surname><given-names>JD</given-names></name><name><surname>Crawford</surname><given-names>ED</given-names></name><name><surname>Goodman</surname><given-names>GE</given-names></name><name><surname>Claudio</surname><given-names>J</given-names></name><name><surname>Winquist</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers</article-title><source>JAMA</source><year>2009</year><volume>301</volume><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">19066370</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kristal</surname><given-names>AR</given-names></name><name><surname>Darke</surname><given-names>AK</given-names></name><name><surname>Morris</surname><given-names>JS</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><name><surname>Goodman</surname><given-names>PJ</given-names></name><name><surname>Thompson</surname><given-names>IM</given-names></name><name><surname>Meyskens</surname><given-names>FL</given-names></name><name><surname>Goodman</surname><given-names>GE</given-names></name><name><surname>Minasian</surname><given-names>LM</given-names></name><name><surname>Parnes</surname><given-names>HL</given-names></name><name><surname>Lippman</surname><given-names>SM</given-names></name><name><surname>Klein</surname><given-names>EA</given-names></name></person-group><article-title>Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk</article-title><source>Journal of the National Cancer Institute</source><pub-id pub-id-type="doi">10.1093/jnci/djt456</pub-id><year>2014</year></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Algotar</surname><given-names>AM</given-names></name><name><surname>Stratton</surname><given-names>MS</given-names></name><name><surname>Ahmann</surname><given-names>FR</given-names></name><name><surname>Ranger-Moore</surname><given-names>J</given-names></name><name><surname>Nagle</surname><given-names>RB</given-names></name><name><surname>Thompson</surname><given-names>PA</given-names></name><name><surname>Slate</surname><given-names>E</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Dalkin</surname><given-names>BL</given-names></name><name><surname>Sindhwani</surname><given-names>P</given-names></name><name><surname>Holmes</surname><given-names>MA</given-names></name><name><surname>Tuckey</surname><given-names>JA</given-names></name><name><surname>Graham</surname><given-names>DL</given-names></name><name><surname>Parnes</surname><given-names>HL</given-names></name><name><surname>Clark</surname><given-names>LC</given-names></name><name><surname>Stratton</surname><given-names>SP</given-names></name></person-group><article-title>Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer</article-title><source>Prostate</source><year>2013</year><volume>73</volume><fpage>328</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">22887343</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>EA</given-names></name><name><surname>Thompson</surname><given-names>IM</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><name><surname>Crowley</surname><given-names>JJ</given-names></name><name><surname>Lucia</surname><given-names>MS</given-names></name><name><surname>Goodman</surname><given-names>PJ</given-names></name><name><surname>Minasian</surname><given-names>LM</given-names></name><name><surname>Ford</surname><given-names>LG</given-names></name><name><surname>Parnes</surname><given-names>HL</given-names></name><name><surname>Gaziano</surname><given-names>JM</given-names></name><name><surname>Karp</surname><given-names>DD</given-names></name><name><surname>Lieber</surname><given-names>MM</given-names></name><name><surname>Walther</surname><given-names>PJ</given-names></name><name><surname>Klotz</surname><given-names>L</given-names></name><name><surname>Parsons</surname><given-names>JK</given-names></name><name><surname>Chin</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Vitamin E and the Risk of Prostate Cancer</article-title><source>JAMA</source><year>2011</year><volume>306</volume><fpage>1549</fpage><lpage>1556</lpage><pub-id pub-id-type="pmid">21990298</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fairweather-Tait</surname><given-names>SJ</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Broadley</surname><given-names>MR</given-names></name><name><surname>Collings</surname><given-names>R</given-names></name><name><surname>Ford</surname><given-names>D</given-names></name><name><surname>Hesketh</surname><given-names>JE</given-names></name><name><surname>Hurst</surname><given-names>R</given-names></name></person-group><article-title>Selenium in human health and disease</article-title><source>Antioxid Redox Signal</source><year>2011</year><volume>14</volume><fpage>1337</fpage><lpage>1383</lpage><pub-id pub-id-type="pmid">20812787</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Ozten</surname><given-names>N</given-names></name><name><surname>Bosland</surname><given-names>MC</given-names></name></person-group><article-title>Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges</article-title><source>Nutr Cancer</source><year>2016</year><volume>68</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">26595411</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>R</given-names></name><name><surname>Collings</surname><given-names>R</given-names></name><name><surname>Harvey</surname><given-names>LJ</given-names></name><name><surname>King</surname><given-names>M</given-names></name><name><surname>Hooper</surname><given-names>L</given-names></name><name><surname>Bouwman</surname><given-names>J</given-names></name><name><surname>Gurinovic</surname><given-names>M</given-names></name><name><surname>Fairweather-Tait</surname><given-names>SJ</given-names></name></person-group><article-title>EURRECA&#x02014;Estimating Selenium Requirements for Deriving Dietary Reference Values</article-title><source>Critical Reviews in Food Science and Nutrition</source><year>2013</year><volume>53</volume><fpage>1077</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">23952089</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Algotar</surname><given-names>AM</given-names></name><name><surname>Stratton</surname><given-names>MS</given-names></name><name><surname>Xu</surname><given-names>MJ</given-names></name><name><surname>Dalkin</surname><given-names>BL</given-names></name><name><surname>Nagle</surname><given-names>RB</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Ahmann</surname><given-names>FR</given-names></name><name><surname>Clark</surname><given-names>LC</given-names></name><name><surname>Stratton</surname><given-names>SP</given-names></name></person-group><article-title>Dose-Dependent Effects of Selenized Yeast on Total Selenium Levels in Prostatic Tissue of Men With Prostate Cancer</article-title><source>Nutr Cancer</source><year>2011</year><volume>63</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">21128179</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsavachidou</surname><given-names>D</given-names></name><name><surname>McDonnell</surname><given-names>TJ</given-names></name><name><surname>Wen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Vakar-Lopez</surname><given-names>F</given-names></name><name><surname>Pisters</surname><given-names>LL</given-names></name><name><surname>Pettaway</surname><given-names>CA</given-names></name><name><surname>Wood</surname><given-names>CG</given-names></name><name><surname>Do</surname><given-names>KA</given-names></name><name><surname>Thall</surname><given-names>PF</given-names></name><name><surname>Stephens</surname><given-names>C</given-names></name><name><surname>Efstathiou</surname><given-names>E</given-names></name><name><surname>Taylor</surname><given-names>R</given-names></name><name><surname>Menter</surname><given-names>DG</given-names></name><name><surname>Troncoso</surname><given-names>P</given-names></name><name><surname>Lippman</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer</article-title><source>J Natl Cancer Inst</source><year>2009</year><volume>101</volume><fpage>306</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">19244175</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groger</surname><given-names>CJ</given-names></name><name><surname>Grubinger</surname><given-names>M</given-names></name><name><surname>Waldhor</surname><given-names>T</given-names></name><name><surname>Vierlinger</surname><given-names>K</given-names></name><name><surname>Mikulits</surname><given-names>W</given-names></name></person-group><article-title>Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e51136</fpage><pub-id pub-id-type="pmid">23251436</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiery</surname><given-names>JP</given-names></name><name><surname>Sleeman</surname><given-names>JP</given-names></name></person-group><article-title>Complex networks orchestrate epithelial-mesenchymal transitions</article-title><source>Nat Rev Mol Cell Biol</source><year>2006</year><volume>7</volume><fpage>131</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">16493418</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>MA</given-names></name></person-group><article-title>Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells</article-title><source>Science</source><year>2013</year><volume>342</volume><issue>6159</issue></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiery</surname><given-names>JP</given-names></name><name><surname>Acloque</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>RY</given-names></name><name><surname>Nieto</surname><given-names>MA</given-names></name></person-group><article-title>Epithelial-mesenchymal transitions in development and disease</article-title><source>Cell</source><year>2009</year><volume>139</volume><fpage>871</fpage><lpage>890</lpage><pub-id pub-id-type="pmid">19945376</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gumustekin</surname><given-names>K</given-names></name><name><surname>Seven</surname><given-names>B</given-names></name><name><surname>Karabulut</surname><given-names>N</given-names></name><name><surname>Aktas</surname><given-names>O</given-names></name><name><surname>Gursan</surname><given-names>N</given-names></name><name><surname>Aslan</surname><given-names>S</given-names></name><name><surname>Keles</surname><given-names>M</given-names></name><name><surname>Varoglu</surname><given-names>E</given-names></name><name><surname>Dane</surname><given-names>S</given-names></name></person-group><article-title>Effects of sleep deprivation, nicotine, and selenium on wound healing in rats</article-title><source>The International journal of neuroscience</source><year>2004</year><volume>114</volume><fpage>1433</fpage><lpage>1442</lpage><pub-id pub-id-type="pmid">15636354</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajpai</surname><given-names>S</given-names></name><name><surname>Mishra</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>H</given-names></name><name><surname>Tripathi</surname><given-names>K</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Pandey</surname><given-names>HP</given-names></name><name><surname>Singh</surname><given-names>RK</given-names></name></person-group><article-title>Effect of selenium on connexin expression, angiogenesis, and antioxidant status in diabetic wound healing</article-title><source>Biol Trace Elem Res</source><year>2011</year><volume>144</volume><fpage>327</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">21633835</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coutinho</surname><given-names>P</given-names></name><name><surname>Qiu</surname><given-names>C</given-names></name><name><surname>Frank</surname><given-names>S</given-names></name><name><surname>Tamber</surname><given-names>K</given-names></name><name><surname>Becker</surname><given-names>D</given-names></name></person-group><article-title>Dynamic changes in connexin expression correlate with key events in the wound healing process</article-title><source>Cell Biology International</source><year>2003</year><volume>27</volume><fpage>525</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">12842092</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>R</given-names></name><name><surname>Power</surname><given-names>KT</given-names></name><name><surname>Wang</surname><given-names>CM</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Becker</surname><given-names>DL</given-names></name></person-group><article-title>Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration</article-title><source>Journal of Cell Science</source><year>2006</year><volume>119</volume><fpage>5193</fpage><lpage>5203</lpage><pub-id pub-id-type="pmid">17158921</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryszawy</surname><given-names>D</given-names></name><name><surname>Sarna</surname><given-names>M</given-names></name><name><surname>Rak</surname><given-names>M</given-names></name><name><surname>Szpak</surname><given-names>K</given-names></name><name><surname>Kedracka-Krok</surname><given-names>S</given-names></name><name><surname>Michalik</surname><given-names>M</given-names></name><name><surname>Siedlar</surname><given-names>M</given-names></name><name><surname>Zuba-Surma</surname><given-names>E</given-names></name><name><surname>Burda</surname><given-names>K</given-names></name><name><surname>Korohoda</surname><given-names>W</given-names></name><name><surname>Madeja</surname><given-names>Z</given-names></name><name><surname>Czyz</surname><given-names>J</given-names></name></person-group><article-title>Functional links between Snail-1 and Cx43 account for the recruitment of Cx43-positive cells into the invasive front of prostate cancer</article-title><source>Carcinogenesis</source><year>2014</year></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Hitomi</surname><given-names>M</given-names></name><name><surname>Bar-Shain</surname><given-names>N</given-names></name><name><surname>Dalimov</surname><given-names>Z</given-names></name><name><surname>Ellis</surname><given-names>L</given-names></name><name><surname>Velpula</surname><given-names>KK</given-names></name><name><surname>Fraizer</surname><given-names>GC</given-names></name><name><surname>Gourdie</surname><given-names>RG</given-names></name><name><surname>Lathia</surname><given-names>JD</given-names></name></person-group><article-title>Connexin 43 expression is associated with increased malignancy in prostate cancer cell lines and functions to promote migration</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>11640</fpage><lpage>11651</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3449</pub-id><pub-id pub-id-type="pmid">25960544</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsuno</surname><given-names>Y</given-names></name><name><surname>Lamouille</surname><given-names>S</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name></person-group><article-title>TGF-&#x003b2; signaling and epithelial&#x02013;mesenchymal transition in cancer progression</article-title><source>Current Opinion in Oncology</source><year>2013</year><volume>25</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1097/CCO.1090b1013e32835b36371</pub-id><pub-id pub-id-type="pmid">23197193</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grande</surname><given-names>JP</given-names></name></person-group><article-title>Role of transforming growth factor-beta in tissue injury and repair</article-title><source>Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine</source><year>1997</year><volume>214</volume><fpage>27</fpage><lpage>40</lpage></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Algotar</surname><given-names>AM</given-names></name><name><surname>Behnejad</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Thompson</surname><given-names>PA</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Stratton</surname><given-names>SP</given-names></name></person-group><article-title>Effect of selenium supplementation on proteomic serum biomarkers in elderly men</article-title><source>The Journal of frailty &#x00026; aging</source><year>2015</year><volume>4</volume><fpage>107</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">26366377</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oettgen</surname><given-names>P</given-names></name><name><surname>Finger</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Akbarali</surname><given-names>Y</given-names></name><name><surname>Thamrongsak</surname><given-names>U</given-names></name><name><surname>Boltax</surname><given-names>J</given-names></name><name><surname>Grall</surname><given-names>F</given-names></name><name><surname>Dube</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>L</given-names></name><name><surname>Quinn</surname><given-names>G</given-names></name><name><surname>Kas</surname><given-names>K</given-names></name><name><surname>Endress</surname><given-names>G</given-names></name><name><surname>Kunsch</surname><given-names>C</given-names></name><name><surname>Libermann</surname><given-names>TA</given-names></name></person-group><article-title>PDEF, a Novel Prostate Epithelium-specific Ets Transcription Factor, Interacts with the Androgen Receptor and Activates Prostate-specific Antigen Gene Expression</article-title><source>Journal of Biological Chemistry</source><year>2000</year><volume>275</volume><fpage>1216</fpage><lpage>1225</lpage><pub-id pub-id-type="pmid">10625666</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steffan</surname><given-names>JJ</given-names></name><name><surname>Koul</surname><given-names>HK</given-names></name></person-group><article-title>Prostate derived ETS factor (PDEF): A putative tumor metastasis suppressor</article-title><source>Cancer Letters</source><year>2011</year><volume>310</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">21764212</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>M</given-names></name><name><surname>Koul</surname><given-names>S</given-names></name><name><surname>Koul</surname><given-names>HK</given-names></name></person-group><article-title>The transcription factor sterile alpha motif (SAM) pointed domain-containing ETS transcription factor (SPDEF) is required for E-cadherin expression in prostate cancer cells</article-title><source>J Biol Chem</source><year>2013</year><volume>288</volume><fpage>12222</fpage><lpage>12231</lpage><pub-id pub-id-type="pmid">23449978</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Zerbini</surname><given-names>LF</given-names></name><name><surname>Otu</surname><given-names>HH</given-names></name><name><surname>Bhasin</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Joseph</surname><given-names>MG</given-names></name><name><surname>Grall</surname><given-names>F</given-names></name><name><surname>Onatunde</surname><given-names>T</given-names></name><name><surname>Correa</surname><given-names>RG</given-names></name><name><surname>Libermann</surname><given-names>TA</given-names></name></person-group><article-title>Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>4219</fpage><lpage>4226</lpage><pub-id pub-id-type="pmid">17483333</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>TR</given-names></name><name><surname>Koul</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>B</given-names></name><name><surname>Khandrika</surname><given-names>L</given-names></name><name><surname>Venezia</surname><given-names>S</given-names></name><name><surname>Maroni</surname><given-names>PD</given-names></name><name><surname>Meacham</surname><given-names>RB</given-names></name><name><surname>Koul</surname><given-names>HK</given-names></name></person-group><article-title>Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: regulation of MMP 9 by PDEF</article-title><source>Mol Cancer</source><year>2010</year><volume>9</volume><fpage>148</fpage><pub-id pub-id-type="pmid">20550708</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steffan</surname><given-names>JJ</given-names></name><name><surname>Koul</surname><given-names>S</given-names></name><name><surname>Meacham</surname><given-names>RB</given-names></name><name><surname>Koul</surname><given-names>HK</given-names></name></person-group><article-title>The Transcription Factor SPDEF Suppresses Prostate Tumor Metastasis</article-title><source>Journal of Biological Chemistry</source><year>2012</year><volume>287</volume><fpage>29968</fpage><lpage>29978</lpage><pub-id pub-id-type="pmid">22761428</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghadersohi</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Azrak</surname><given-names>RG</given-names></name><name><surname>Wilding</surname><given-names>GE</given-names></name><name><surname>Manjili</surname><given-names>MH</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer</article-title><source>The Prostate</source><year>2011</year><volume>71</volume><fpage>1178</fpage><lpage>1188</lpage><pub-id pub-id-type="pmid">21656828</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>C</given-names></name><name><surname>Baghdadi</surname><given-names>H</given-names></name><name><surname>Howie</surname><given-names>AF</given-names></name><name><surname>Mason</surname><given-names>JI</given-names></name><name><surname>Walker</surname><given-names>SW</given-names></name><name><surname>Beckett</surname><given-names>GJ</given-names></name></person-group><article-title>Selenium supplementation attenuates procollagen-1 and interleukin-8 production in fat-loaded human C3A hepatoblastoma cells treated with TGFb1</article-title><source>Biochimica et Biophysica Acta</source><year>2010</year><volume>1800</volume><fpage>611</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">20188144</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name></person-group><article-title>Sodium selenite inhibits the expression of VEGF, TGFbeta(1) and IL-6 induced by LPS in human PC3 cells via TLR4-NF-(K)B signaling blockage</article-title><source>Int Immunopharmacol</source><year>2010</year><volume>10</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">19811770</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Briske-Anderson</surname><given-names>M</given-names></name><name><surname>Idso</surname><given-names>JP</given-names></name><name><surname>Hunt</surname><given-names>CD</given-names></name></person-group><article-title>The Selenium Metabolite Methylselenol Inhibits the Migration and Invasion Potential of HT1080 Tumor Cells</article-title><source>The Journal of Nutrition</source><year>2006</year><volume>136</volume><fpage>1528</fpage><lpage>1532</lpage><pub-id pub-id-type="pmid">16702316</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrickx</surname><given-names>W</given-names></name><name><surname>Decock</surname><given-names>J</given-names></name><name><surname>Mulholland</surname><given-names>F</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Fairweather-Tait</surname><given-names>S</given-names></name></person-group><article-title>Selenium Biomarkers in Prostate Cancer Cell Lines and Influence of Selenium on Invasive Potential of PC3 Cells</article-title><source>Frontiers in oncology</source><year>2013</year><volume>3</volume><fpage>239</fpage><pub-id pub-id-type="pmid">24066278</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukamoto</surname><given-names>T</given-names></name><name><surname>Hama</surname><given-names>S</given-names></name><name><surname>Kogure</surname><given-names>K</given-names></name><name><surname>Tsuchiya</surname><given-names>H</given-names></name></person-group><article-title>Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation</article-title><source>Experimental cell research</source><year>2013</year><volume>319</volume><fpage>1913</fpage><lpage>1921</lpage><pub-id pub-id-type="pmid">23769801</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Anderson</surname><given-names>LB</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Witthuhn</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name></person-group><article-title>Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds</article-title><source>Nutr Cancer</source><year>2011</year><volume>63</volume><fpage>778</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">21614726</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>EC</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Kengeri</surname><given-names>SS</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Combs</surname><given-names>GF</given-names></name><name><surname>Morris</surname><given-names>JS</given-names></name><name><surname>Bostwick</surname><given-names>DG</given-names></name><name><surname>Waters</surname><given-names>DJ</given-names></name></person-group><article-title>Defining the Optimal Selenium Dose for Prostate Cancer Risk Reduction: Insights from the U-Shaped Relationship between Selenium Status, DNA Damage, and Apoptosis (a publication of International Hormesis Society)</article-title><source>Dose-response</source><year>2009</year><volume>8</volume><fpage>285</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">20877485</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayman</surname><given-names>MP</given-names></name></person-group><article-title>Selenium and human health</article-title><source>The Lancet</source><year>2012</year><volume>379</volume><fpage>1256</fpage><lpage>1268</lpage></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayman</surname><given-names>MP</given-names></name><name><surname>Infante</surname><given-names>HG</given-names></name><name><surname>Sargent</surname><given-names>M</given-names></name></person-group><article-title>Food-chain selenium and human health: spotlight on speciation</article-title><source>The British journal of nutrition</source><year>2008</year><volume>100</volume><fpage>238</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">18346307</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hesketh</surname><given-names>J</given-names></name></person-group><article-title>Nutrigenomics and selenium: gene expression patterns, physiological targets, and genetics</article-title><source>Annu Rev Nutr</source><year>2008</year><volume>28</volume><fpage>157</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">18494599</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayman</surname><given-names>MP</given-names></name></person-group><article-title>Selenoproteins and human health: insights from epidemiological data</article-title><source>Biochimica et biophysica acta</source><year>2009</year><volume>1790</volume><fpage>1533</fpage><lpage>1540</lpage><pub-id pub-id-type="pmid">19327385</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinnott</surname><given-names>JA</given-names></name><name><surname>Rider</surname><given-names>JR</given-names></name><name><surname>Carlsson</surname><given-names>J</given-names></name><name><surname>Gerke</surname><given-names>T</given-names></name><name><surname>Tyekucheva</surname><given-names>S</given-names></name><name><surname>Penney</surname><given-names>KL</given-names></name><name><surname>Sesso</surname><given-names>HD</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Fall</surname><given-names>K</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Mucci</surname><given-names>LA</given-names></name><name><surname>Pawitan</surname><given-names>Y</given-names></name><name><surname>Andersson</surname><given-names>SO</given-names></name><name><surname>Andren</surname><given-names>O</given-names></name></person-group><article-title>Molecular differences in transition zone and peripheral zone prostate tumors</article-title><source>Carcinogenesis</source><year>2015</year><volume>36</volume><fpage>632</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">25870172</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gianduzzo</surname><given-names>TR</given-names></name><name><surname>Holmes</surname><given-names>EG</given-names></name><name><surname>Tinggi</surname><given-names>U</given-names></name><name><surname>Shahin</surname><given-names>M</given-names></name><name><surname>Mactaggart</surname><given-names>P</given-names></name><name><surname>Nicol</surname><given-names>D</given-names></name></person-group><article-title>Prostatic and peripheral blood selenium levels after oral supplementation</article-title><source>J Urol</source><year>2003</year><volume>170</volume><fpage>870</fpage><lpage>873</lpage><pub-id pub-id-type="pmid">12913719</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabichi</surname><given-names>AL</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Taylor</surname><given-names>RJ</given-names></name><name><surname>Thompson</surname><given-names>IM</given-names></name><name><surname>Miles</surname><given-names>BJ</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><name><surname>Minasian</surname><given-names>LM</given-names></name><name><surname>Pisters</surname><given-names>LL</given-names></name><name><surname>Caton</surname><given-names>JR</given-names></name><name><surname>Basler</surname><given-names>JW</given-names></name><name><surname>Lerner</surname><given-names>SP</given-names></name><name><surname>Menter</surname><given-names>DG</given-names></name><name><surname>Marshall</surname><given-names>JR</given-names></name><name><surname>Crawford</surname><given-names>ED</given-names></name><name><surname>Lippman</surname><given-names>SM</given-names></name></person-group><article-title>Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>2178</fpage><lpage>2184</lpage><pub-id pub-id-type="pmid">16609032</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayman</surname><given-names>MP</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Bekaert</surname><given-names>B</given-names></name><name><surname>Catterick</surname><given-names>J</given-names></name><name><surname>Galassini</surname><given-names>R</given-names></name><name><surname>Hall</surname><given-names>E</given-names></name><name><surname>Warren-Perry</surname><given-names>M</given-names></name><name><surname>Beckett</surname><given-names>GJ</given-names></name></person-group><article-title>Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>87</volume><fpage>370</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">18258627</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravn-Haren</surname><given-names>G</given-names></name><name><surname>Krath</surname><given-names>BN</given-names></name><name><surname>Overvad</surname><given-names>K</given-names></name><name><surname>Cold</surname><given-names>S</given-names></name><name><surname>Moesgaard</surname><given-names>S</given-names></name><name><surname>Larsen</surname><given-names>EH</given-names></name><name><surname>Dragsted</surname><given-names>LO</given-names></name></person-group><article-title>Effect of long-term selenium yeast intervention on activity and gene expression of antioxidant and xenobiotic metabolising enzymes in healthy elderly volunteers from the Danish Prevention of Cancer by Intervention by Selenium (PRECISE) pilot study</article-title><source>Br J Nutr</source><year>2008</year><volume>99</volume><fpage>1190</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">18062829</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayman</surname><given-names>MP</given-names></name></person-group><article-title>The use of high-selenium yeast to raise selenium status: how does it measure up?</article-title><source>The British journal of nutrition</source><year>2004</year><volume>92</volume><fpage>557</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">15522125</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>EH</given-names></name><name><surname>Hansen</surname><given-names>M</given-names></name><name><surname>Paulin</surname><given-names>H</given-names></name><name><surname>Moesgaard</surname><given-names>S</given-names></name><name><surname>Reid</surname><given-names>M</given-names></name><name><surname>Rayman</surname><given-names>M</given-names></name></person-group><article-title>Speciation and bioavailability of selenium in yeast-based intervention agents used in cancer chemoprevention studies</article-title><source>Journal of AOAC International</source><year>2004</year><volume>87</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">15084104</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Dael</surname><given-names>P</given-names></name><name><surname>Van Cauwenbergh</surname><given-names>R</given-names></name><name><surname>Robberecht</surname><given-names>H</given-names></name><name><surname>Deelstra</surname><given-names>H</given-names></name><name><surname>Calomme</surname><given-names>M</given-names></name></person-group><article-title>Determination of selenium in human serum using electrothermal atomization with longitudinal Zeeman-effect background correction or flow injection hydride generation</article-title><source>At Spectrosc</source><year>1995</year><volume>16</volume><fpage>251</fpage><lpage>255</lpage></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>R</given-names></name><name><surname>Hooper</surname><given-names>L</given-names></name><name><surname>Norat</surname><given-names>T</given-names></name><name><surname>Lau</surname><given-names>R</given-names></name><name><surname>Aune</surname><given-names>D</given-names></name><name><surname>Greenwood</surname><given-names>DC</given-names></name><name><surname>Vieira</surname><given-names>R</given-names></name><name><surname>Collings</surname><given-names>R</given-names></name><name><surname>Harvey</surname><given-names>LJ</given-names></name><name><surname>Sterne</surname><given-names>JA</given-names></name><name><surname>Beynon</surname><given-names>R</given-names></name><name><surname>Savovi&#x00107;</surname><given-names>J</given-names></name><name><surname>Fairweather-Tait</surname><given-names>SJ</given-names></name></person-group><article-title>Selenium and prostate cancer: systematic review and meta-analysis</article-title><source>The American Journal of Clinical Nutrition</source><year>2012</year><volume>96</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">22648711</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geybels</surname><given-names>MS</given-names></name><name><surname>Verhage</surname><given-names>BA</given-names></name><name><surname>van Schooten</surname><given-names>FJ</given-names></name><name><surname>Goldbohm</surname><given-names>RA</given-names></name><name><surname>van den Brandt</surname><given-names>PA</given-names></name></person-group><article-title>Advanced prostate cancer risk in relation to toenail selenium levels</article-title><source>J Natl Cancer Inst</source><year>2013</year><volume>105</volume><fpage>1394</fpage><lpage>1401</lpage><pub-id pub-id-type="pmid">23878355</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Boyd</surname><given-names>AD</given-names></name><name><surname>Kostov</surname><given-names>G</given-names></name><name><surname>Athey</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>EG</given-names></name><name><surname>Bunney</surname><given-names>WE</given-names></name><name><surname>Myers</surname><given-names>RM</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name><name><surname>Akil</surname><given-names>H</given-names></name><name><surname>Watson</surname><given-names>SJ</given-names></name><name><surname>Meng</surname><given-names>F</given-names></name></person-group><article-title>Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data</article-title><source>Nucleic Acids Research</source><volume>33</volume><fpage>e175</fpage><pub-id pub-id-type="pmid">16284200</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Hobbs</surname><given-names>B</given-names></name><name><surname>Collin</surname><given-names>F</given-names></name><name><surname>Beazer-Barclay</surname><given-names>YD</given-names></name><name><surname>Antonellis</surname><given-names>KJ</given-names></name><name><surname>Scherf</surname><given-names>U</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name></person-group><article-title>Exploration, normalization, and summaries of high density oligonucleotide array probe level data</article-title><source>Biostatistics</source><year>2003</year><volume>4</volume><fpage>249</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">12925520</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>Linear models and empirical bayes methods for assessing differential expression in microarray experiments</article-title><source>Stat Appl Genet Mol Biol</source><year>2004</year><volume>3</volume><fpage>Article3</fpage><pub-id pub-id-type="pmid">16646809</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>2005</year><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smoot</surname><given-names>ME</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Ruscheinski</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>P-L</given-names></name><name><surname>Ideker</surname><given-names>T</given-names></name></person-group><article-title>Cytoscape 2.8: new features for data integration and network visualization</article-title><source>Bioinformatics</source><year>2011</year><volume>27</volume><fpage>431</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">21149340</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merico</surname><given-names>D</given-names></name><name><surname>Isserlin</surname><given-names>R</given-names></name><name><surname>Stueker</surname><given-names>O</given-names></name><name><surname>Emili</surname><given-names>A</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name></person-group><article-title>Enrichment map: a network-based method for gene-set enrichment visualization and interpretation</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><fpage>e13984</fpage><pub-id pub-id-type="pmid">21085593</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Llamas</surname><given-names>C</given-names></name><name><surname>Lopez-Bigas</surname><given-names>N</given-names></name></person-group><article-title>Gitools: analysis and visualisation of genomic data using interactive heat-maps</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><fpage>e19541</fpage><pub-id pub-id-type="pmid">21602921</pub-id></element-citation></ref></ref-list></back></article>